Literature DB >> 16250025

Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset.

Georgios M Hadjigeorgiou1, Georgia Xiromerisiou, Vanessa Gourbali, Kostantinos Aggelakis, Nikolaos Scarmeas, Alexandros Papadimitriou, Andrew Singleton.   

Abstract

The alpha-synuclein Rep1 polymorphism was studied in patients and controls in an ethnic Greek population. There was an association of allele 2 with risk of Parkinson's disease (PD; adjusted odd ratio = 3.25; 95% CI = 1.80-5.87). Survival analyses (Cox proportional hazards models) were employed to explore the influence of genotypes on age at onset of PD. Age at onset of carriers of at least one Rep1 allele 2 was earlier (3.6 years) compared to noncarriers (adjusted hazard ratio = 2.21; 95% CI = 1.58-3.10). Kaplan-Meier analysis also supported a dosage effect of Rep1 allele 2 on age at onset. For Rep1 allele 1, there was neither association with risk of PD nor influence on age at onset. This is the first study showing an influence of Rep1 polymorphism on age at onset of PD. Copyright 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16250025     DOI: 10.1002/mds.20752

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

1.  SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder.

Authors:  M Toffoli; E Dreussi; E Cecchin; M Valente; N Sanvilli; M Montico; S Gagno; M Garziera; M Polano; M Savarese; G Calandra-Buonaura; F Placidi; M Terzaghi; G Toffoli; G L Gigli
Journal:  Neurol Sci       Date:  2017-04-13       Impact factor: 3.307

2.  The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome.

Authors:  Suna Lahut; David Vadasz; Candan Depboylu; Vincent Ries; Martina Krenzer; Karin Stiasny-Kolster; A Nazli Basak; Wolfgang H Oertel; Georg Auburger
Journal:  Neurogenetics       Date:  2014-05-27       Impact factor: 2.660

Review 3.  Diagnosis and treatment of Parkinson disease: molecules to medicine.

Authors:  Joseph M Savitt; Valina L Dawson; Ted M Dawson
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

Review 4.  Genetic variability in SNCA and Parkinson's disease.

Authors:  Lasse Pihlstrøm; Mathias Toft
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

5.  Variant in the 3' region of SNCA associated with Parkinson's disease and serum α-synuclein levels.

Authors:  Yacen Hu; Beisha Tang; Jifeng Guo; Xintian Wu; Qiying Sun; Changhe Shi; Liang Hu; Chunyu Wang; Lei Wang; Liming Tan; Lu Shen; Xinxiang Yan; Hainan Zhang
Journal:  J Neurol       Date:  2011-08-19       Impact factor: 4.849

6.  Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells.

Authors:  Li-Wen Ko; Hwai-Hwa C Ko; Wen-Lang Lin; Jayanranyan G Kulathingal; Shu-Hui C Yen
Journal:  J Neuropathol Exp Neurol       Date:  2008-11       Impact factor: 3.685

7.  Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of α-synuclein oligomers and decrease of neurites.

Authors:  Peizhou Jiang; Ming Gan; Abdul Shukkur Ebrahim; Monica Castanedes-Casey; Dennis W Dickson; Shu-Hui C Yen
Journal:  Neurobiol Aging       Date:  2012-11-28       Impact factor: 4.673

Review 8.  Genetic susceptibility in Parkinson's disease.

Authors:  Jose Miguel Bras; Andrew Singleton
Journal:  Biochim Biophys Acta       Date:  2008-11-20

9.  Alpha-synuclein and familial Parkinson's disease.

Authors:  Nathan Pankratz; William C Nichols; Veronika E Elsaesser; Michael W Pauciulo; Diane K Marek; Cheryl A Halter; Joanne Wojcieszek; Alice Rudolph; Ronald F Pfeiffer; Tatiana Foroud
Journal:  Mov Disord       Date:  2009-06-15       Impact factor: 10.338

10.  Alpha-synuclein repeat variants and survival in Parkinson's disease.

Authors:  Sun Ju Chung; Joanna M Biernacka; Sebastian M Armasu; Kari Anderson; Roberta Frigerio; Jan O Aasly; Grazia Annesi; Anna Rita Bentivoglio; Laura Brighina; Marie-Christine Chartier-Harlin; Stefano Goldwurm; Georgios Hadjigeorgiou; Barbara Jasinska-Myga; Beom Seok Jeon; Yun Joong Kim; Rejko Krüger; Suzanne Lesage; Katerina Markopoulou; George Mellick; Karen E Morrison; Andreas Puschmann; Eng-King Tan; David Crosiers; Jessie Theuns; Christine Van Broeckhoven; Karin Wirdefeldt; Zbigniew K Wszolek; Alexis Elbaz; Demetrius M Maraganore
Journal:  Mov Disord       Date:  2014-02-27       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.